Different interpretations have been provided by Perrella et al. [I] to explain the expansion of TCS-Fl+/A13+ cells in the peripheral blood, including selective stimulation of Vsl subset by I? curinii and/or involvement of this subset in early host defence against the opportunistic infection. The increase of the V Q + cells observed in the lung, i.e., the microenvironment where the immune response against I? curinii takes place, strongly suggests the alternative hypothesis that target antigens (including F! curinii antigens) and/or environmental stimuli may favour the expansion of the circulating T C R y/6 cell pool and the later selective migration of Vs2+/BB3+ cells &om the peripheral blood to the lung. In this scenario, the depletion of BB3+ cells in the peripheral blood (and the consequent increase in the relative percentage of AlS+/Vsl+ cells) is likely to represent an epiphenomenon, related to the redistribution of V82+ cells to the sites of PCP-associated inflammation. Further studies are also needed to determine whether HIV infection of pulmonary cells (including alveolar macrophages, pulmonary lymphocytes and fibroblasts) [6] may represent an additional factor accounting for the selective local expansion of Vg2+ cells. 
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The results of the intermediate analysis of the AIDS Clinical Trials Group (ACTG) 076/Agence Nationale de Recherches sur le SIDA (ANRS) 024 clinical trial conducted in the USA and France have demonstrated the efficacy of zidovudine (ZDV) in reducing the rate of mother-to-child transmission (MTCT) of HIV-1. These findings have already begun to transform clinical practice in industrialized countries, despite the lack of long-term safety data [l] . Afiica has the highest incidence of perinatally acquired AIDS [2] , but other areas of high incidence/prevalence already exist in developing countries such as Thailand. Decreasing M T C T of HIV-1 must be a public-health priority in this context. If ZDV can be considered as the gold standard for reducing vertical 'transmission in the industrialized world, is it time to shift priorities throughout the world? In pursuing such a goal, it is necessary to face not only the critical problem of cost to individuals and health-care systems, but also the uncertainties about the applicability, tolerance, and even the efficacy of prescriptions derived fiom the ACTG 076 protocol [3] .
The efficacy of ZDV has been demonstrated only under specific conditions: 100mg oral doses five times daily beginning between 14 and 34 weeks of gestation, intravenous infusion during labour and delivery, and administration of ZDV syrup to the neonate four times daily beginning within 24 h ofbirth for 6 weeks. Leaving aside the cost, this protocol is clearly inapplicable in most developing countries. First, it requires that HIV testing, with pre-and post-test counselling, be performed early in pregnancy. Second, the acceptability of medications to be taken several times daily by mother and neonate may often be poor. Third, intravenous infusions during labour/delivery require admission early in labour and the management of intravenous lines may be ineffective, if not dangerous, in maternities lacking trained personnel and sterile conditions. Finally, whereas the ACTG 076 trial was conducted in a non-breastfeeding population, the relevance of these results may be quite different where infants are breastfed [4] .
We therefore suggest that ZDV be introduced in developing countries to decrease MTCT of HIV-1 only if relatively widely applicable protocols are constructed, evaluated and proven to be effective. Among others, the following options may be proposed (Table l) , alone or in combination, considering that late in utero and intrapartum HIV transmissions are thought to be predominant in the timing of acquisition of the infection by the future child [5, 6] : oral ZDV at the end of pregnancy, with a simplified daily schedule; an oral loading dose during labour/delivery; syrup to the neonate; oral ZDV to the mother during some or all the breastfeeding period.
Attempts must be made to apply ZDV to reducing postnatal transmission in a context where breastfeeding will not usually be withheld. The proven benefits of breast milk on perinatal morbidity and mortality are widely thought to outweigh the potential risk of HIV transmission in developing countries, leading the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) to recommend breastfeeding regardless of the maternal HIV infection status [7] . If maternal ZDV therapy is to be given throughout the breastfeeding period, it should be prolonged at least 4-6 months, which is the period recommended by UNICEF for exclusive breastfeeding in its recent Baby-Friendly Initiative [SI. O n the other hand, there is legitimate concern that postnatal transmission occurring despite maternal ZDV treatment and/or following the end of the therapy may cancel the benefit of decreasing in utero and/or intrapartum transmission. The ethical and practical aspects of the controversy over breastfeeding will be I correctly addressed only when the actual contribution of breastfeeding to MTCT of HIV-1 is quantified.
Regardless of the protocol chosen, clinical trials must evaluate not only the efficacy but also the tolerance of ZDV in developing countries. Adverse effects may be different and more frequent than in France and the United States; for example, the prevalence of severe anaemia is high in African pregnant women [9] . Welldesigned Phase II tolerance studies should therefore be a necessary step in evaluating ZDV in developing countries.
In designing clinical trials of ZDV in developing countries, one must answer several diffcult ethical questions. The first is whether the drug can be available afterwards outside of a clinical trial setting [lo] . The main obstacle is cost, which calls for effective negotiations between the public-health authorities of the concerned states, bilateral and international agencies such as WHO, and pharmaceutical companies. Another diffcult ethical problem is whether to perform a placebo-controlled trial. Panels of experts convened by the ANRS in France and WHO in March and June 1994 stressed that placebo-controlled The results of the ACTG 076 trial must encourage researchers in developing countries to design and implement trials to determine the tolerance and efficacy of ZDV and other drug strategies that are likely to be widely applicable in the future. Prospects for an effective intervention should also incite public-health authorities to make prenatal HIV testing available. The international health community has a specific responsibility towards reducing the price of antiretrovirals or other interventions and making such measures available in developing countries if they are proven to be effective. Several trials may be necessary in order to evaluate measures that may apply differently in various parts of the world. The development of a common methodological approach is essential in such trials as it has been for observational studies estimating the rate of MTCT of HIV [13, 14] . Once evaluated and proven to be efficacious, these measures may ultimately be associated in a comprehensive intervention to tackle the increasing problem ofperinatally acquired HIV infection in Af%ca and other developing countries.
